Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.
We review strategic approaches taken over an eight-year period at BMS to implement new high-throughput approaches to lead discovery. Investments in compound management infrastructure and chemistry library production capability allowed significant growth in the size, diversity and quality of the BMS compound collection. Screening platforms were upgraded with robust automated technology to support miniaturized assay formats, while workflows and information handling technologies were streamlined for improved performance. These technology changes drove the need for a supporting organization in which critical engineering, informatics and scientific skills were more strongly represented. Taken together, these investments led to significant improvements in speed and productivity as well a greater impact of screening campaigns on the initiation of new drug discovery programs.
Houston
John G
JG
Department of Applied Biotechnology, Research and Development, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA. John.Houston@bms.com
Banks
Martyn N
MN
Binnie
Alastair
A
Brenner
Stephen
S
O'Connell
Jonathan
J
Petrillo
Edward W
EW
D002201:Capital Expenditures; D015195:Drug Design; D004345:Drug Industry / Q000191:economics*; D007449:Investments; D017149:Private Sector; D013678:Technology, Pharmaceutical / Q000191:economics / Q000379:methods*